C-RAD AB (publ), Interim report 1 January- 30 September 2010
Key events during first quarter - 6 Sentinel systems has been ordered by the Swedish Medical Center in Seattle, USA - IBA Dosimetry has ordered 1400 diode detectors to a value of 4,3 MSEK - The new share issue was oversubscribed by 35 % - Since March 2010 the C-RAD B-share is listed at NASDAQ OMX First North Premier - A subsidiary called C-RAD Inc. has been founded for distribution of C-RAD solutions in the US - New distributors in China, India and German speaking nations - GEMini ED and Sentinel with new functionality have been exhibited at major conferences in the US and Europe - Sales of 10,0 MSEK (1,7 MSEK) - Profit after tax of - 6 618 kSEK (-9 085 kSEK) - Earnings per share after tax of -0,54 SEK (- 0,95 SEK) - Operating profit of -5 773 kSEK (-8 792 kSEK) - Equity ratio of 78 % (77 %) - Cash of 19 004 kSEK (7 215 kSEK) - Numbers of employees were 19 (18). Key events after the close of the reporting period - An agreement has been signed with Varian Medical Systems - C-RAD is developing the organization in the US. The agreement with Radiation Oncology Systems has been cancelled - The German company LAP has been sued by the subsidiary C-RAD Positioning AB due to breach of contract - A clinical cooperation agreement has been signed with the University Hospital in Mannheim Comments by Erik Hedlund, president of C-RAD AB. “So far the company has during last quarter generated the largest sales volume ever. This is due to major investments in R/D and a build up of quality systems to fulfil the high requirements in the field of radiation therapy. C-RAD is establishing direct sales channels to key markets. The company has appointed sales managers in Scandinavia and in the US. The agreements with Elekta, IBA and Varian will in coming years be of great importance.”